Details for New Drug Application (NDA): 202912
✉ Email this page to a colleague
NDA 202912 describes ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, which is a drug marketed by Lupin Ltd and is included in one NDA. Additional details are available on the ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE profile page.
The generic ingredient in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
The generic ingredient in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
Summary for 202912
| Tradename: | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE |
| Applicant: | Lupin Ltd |
| Ingredient: | abacavir sulfate; lamivudine; zidovudine |
| Patents: | 0 |
Pharmacology for NDA: 202912
| Mechanism of Action | Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE;150MG;300MG | ||||
| Approval Date: | Dec 5, 2013 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
